Bymaster FP, Lee TC, Knadler MP, et al. 2005. The dual transport inhibitor duloxetine: A review of its preclinical pharmacology, pharmaco- kinetic proﬁle and clinical results in depression. Curr Pharm Des, 11:1475–93. Carter RM, Wittchen H-U, Pﬁsster H, et al. 2001. One-year prevalence of subthreshold and threshold DSM-IV generalised anxiety disorder in a nationally representative sample. Depress Anxiety, 13:78–88. Chan C, Yeo KP, Pan AX, et al. 2007. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol, 63:310–14. Davidson JR. 2001. Pharmacotherapy of generalised anxiety disorder. J Clin Psychiatry, 62(Suppl 11):46–50. Davidson JR, Allqulander C, Pollack MH, et al. 2008. Efﬁcacy and tolerabil- ity of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol, 23:519–23. Dunner DL, Goldstein DJ, Mallinckrodt C, et al. 2003. Duloxetine in the treatment of anxiety symptoms associated with depression. Depress Anxiety, 18:53–61. Durham R, Chambers JA, Power KG, et al. 2005. Long-term outcome of cognitive behaviour therapy clinical trials in Scotland. Health Technol Assess, 9:1–174. Durham RC, Murphy T, Allan T, et al. 1994. Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder. Br J Psychiatry, 165:315–23. EMEA. ICH Topic E9: Statistical principles for clinical trials (CPMP/ ICH/363/96), 1998. Endicott J, Russell JW, Raskin J, et al. 2007. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: Three independent studies. J Clin Psychiatry, 68:518–24. Engleman ES, Perry KW, Mayle DA, et al. 1995. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology, 12:287–95. Fermini B, Fossa AA. 2003. The impact of drug-induced QT interval pro- longation on drug discovery. Nat Rev Drug Discov, 2:439–47. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin, 23:175–84. Goldstein DJ, Lu Y, Detke MJ, et al. 2004. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol, 24:389–99. Goldstein DJ, Mallinckrodt C, Lu Y, et al. 2002. Duloxetine in the treat- ment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry, 63:225. Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry, 63:17–23. Gould RA, Otto MW, Pollack MH, et al. 1997. Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a prelimi- nary meta-analysis. Behav Res Ther, 28:285–305. Healy D, Cattell D. 2003. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry, 183:22–7. Hidalgo RB, Tupler LA, Davidson JRT. 2007. An effect size analysis of pharmacologic treatments for generalised anxiety disorder. J Psycho- pharmacol, 21:864–72. Hudson JI, Wohlreich MM, Kajdasz DK. 2005. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psycho- pharmacol, 20:327–41. Kasamo K, Blier P, de Montigny C. 1996. Blockade of serotonin and norepininephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther, 277:278–86. Kessler RC, Chiu TW, Demler O, et al. 2005. Prevalence, severity and comorbidity of 12-month DSM-IV disorders in the National Comorbid- ity Survey Replication. Arch Gen Psychiatry, 62:617–27. Kingdon D, Tyrer P, Seivewright N, et al. 1996. The Nottingham Study of Neurotic Disorder: inﬂuence of cognitive therapists on outcome. Br J Psychiatry, 169:93–7. Neuropsychiatric Disease and Treatment 2008:4(6) Duloxetine for GAD Koponen H, Allgulander C, Erickson J, et al. 2007. Efﬁcacy of duloxetine for the treatment of generalized anxiety disorder: Implications for primary physicians. Prim Care Companion J Clin Psychiatry, 9:100–7. Lam RW. 2006. Generalized anxiety disorder: how to treat and for how long? Int J Psychiatr Clin Pract, 10:10–15. Lantz RJ, Gillespie TA, Rash TJ, et al. 2003. Metabolism, excretion and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos, 31:1142–50. Lieb R, Becker E, Altamura C. 2005. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol, 15:445–52. Lieb R, Isenee B, von Sydow K, et al. 2000. The early stages of psycho- pathology study (EDSP), a methodological update. Eur Addict Res, 6:170–82. NICE. Clinical Guideline 22. 2004. Anxiety: Management of anxiety (panic disorder, with or without agoraphobia and generalised anxiety disorder) in adults in primary, secondary and community care. URL: www.nice. orh.uk/CG022NICEguideline. Nicolini H, Bakish D, Duenas H, et al. 2008. Improvements of psychic and somatic symptoms in adult patients with genearalised anxiety disorder: examination froma a duloxetine, venlafaxine extended release and placebo trial. Psychol Med, doi:10.1017/S0033291708003401. Parikh AR, Thatcher BT, Tamano EA. 2008. Suicidal ideation associated with duloxetine use. J Clin Psychopharmacol, 28:101–2. Perlis RH, Perlis CS, Wu Y, et al. 2005. Industry sponsorship and ﬁnancial conﬂict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry, 162:1957–60. Rynn M, Russell J, Erickson J, et al. 2007. Efﬁcacy and safety of duloxetine in the treatment of generalized anxiety disorder: A flexible dose, progressive-titration, placebo controlled trial. Depress Anxiety, 22:1–8. Shader RI, Greenblatt DJ. 1993. Use of benzodiazepines in anxiety disorders. N Engl J Med, 328:1398–405. Sharma A, Goldberg MJ, Cerimele BJ. 2000. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol, 40:161–7. Skinner MH, Kuan Han-Yi, Skerjanec A, et al. 2003. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol, 57:54–61. Skinner MH, Skerjanec A, Seger M, et al. 2000. The effect of food and bedtime administration on duloxetine pharmacokinetics. Clin Phar- macol Ther, 67:129. Stahl SM, Grady MM, Moret C, et al. 2005. SNRIs: Their pharmacology, clinical efﬁcacy and tolerability in comparison with other classes of antidepressants. CNS Spectr, 10:732–47. Suri A, Reddy S, Gonzales C, et al. 2005. Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Int J Clin Pharmacol Ther, 43:78–84. Tianmei S, Knadler MP, Lim MT, et al. 2007. Pharmacokinetics and toler- ability of duloxetine following oral administration to healthy Chinese subjects. Clin Pharmacokinet, 46:767–5. Troelsen KB, Nielsen EO, Mirza NR. 2005. Chronic treatment with dulox- etine is necessary for an anxiolytic-like response inthe mouse zero maze: the role of the serotonin transporter. Psychopharmacology, 181:741–50. Turcotte JE, Debonnel G, de Montigny C, et al. 2001. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology, 24:511–21. Turner EH, Matthews AM, Lindardatos E, et al. 2008. Selective publication of antidepressant trials and its inﬂuence on apparent efﬁcacy. N Engl J Med, 358:252–60. Tyrer P, Baldwin D. 2006. Generalised anxiety disorder. Lancet, 368 :2156–64. Vincent S, Bieck PR, Garland EM, et al. 2004. Clinical assessment of norepinephrine transporter blockade through biochemical and phar- macological proﬁles. Circulation, 109:3202–7. Wernicke J, Lledo A, Raskin J, et al. 2007. An evaluation of the cardiovas- cular safety proﬁle of duloxetine: ﬁndings from 42 placebo-controlled studies. Drug Saf, 30:437–55. 1179